PND44 Validation of the Fabry Outcome Survey (FOS) Paediatric Health and Pain Questionnaire
Mireia Raluy(United BioSource Corporation (United Kingdom)), M. Beck(University of Applied Sciences Mainz), Catharina Whybra(Johannes Gutenberg University Mainz), Uma Ramaswami(The Royal Free Hospital), Guillem Pintos‐Morell(Hospital Universitari Germans Trias i Pujol), Gisela Kalkum(Johannes Gutenberg University Mainz), Ingela Wiklund(St George's, University of London), Rossella Parini(MRC Epidemiology Unit), Marianne Rohrbach(Ghent University Hospital), Donald E. Stull(IQVIA (United States)), W.H. Chen
Cited by 0
Related Papers
Development and first validation of the COPD Assessment Test
|European Respiratory Journal|2009|3.2k
The 2017 international classification of the Ehlers–Danlos syndromes
|American Journal of Medical Genetics Part C Seminars in Medical Genetics|2017|1.9k
Optimal recall periods for patient-reported outcomes: challenges and potential solutions
|Current Medical Research and Opinion|2009|413
Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document
|Orphanet Journal of Rare Diseases|2015|345
Mutations in SLC39A14 disrupt manganese homeostasis and cause childhood-onset parkinsonism–dystonia
|Nature Communications|2016|326